

```
=> File .Biotech
=> s (somatostatin (2a) 5 (2a) receptor# orsstr(w)5)
L1      579 (SOMATOSTATIN (2A) 5 (2A) RECEPTOR# OR SSTR(W) 5)
```

```
=> s l1 and (hyperlipid? or lipidem?)
L2      8 L1 AND (HYPERLIPID? OR LIPIDEM?)
```

```
=> s l1 and (triacylglycerol or glycerol or cholestrol)
L3      15 L1 AND (TRIACYGLYCEROL OR GLYCEROL OR CHOLESTROL)
```

```
=> s l2 and l3
L4      6 L2 AND L3
```

```
=> s l3 and (treat? or lower?)
L5      15 L3 AND (TREAT? OR LOWER?)
```

```
=> s l2 and l5
L6      6 L2 AND L5
```

```
=> dis l2 1-8 bib ab
```

```
L2  ANSWER 1 OF 8  CAPLUS  COPYRIGHT 2002 ACS
AN  1999:808645  CAPLUS
DN  132:44983
TI  Method using a type 5 selective somatostatin agonist for treating
    hyperlipidemia
IN  Cawthorne, Michael Anthony; Liu, Yong-Ling; Sennitt, Matthew V.
PA  Biomeasure, Incorporated, USA
SO  U.S., 8 pp.
    CODEN: USXXAM
DT  Patent
LA  English
FAN.CNT 1
```

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6004928	A	19991221	US 1998-78111	19980513
PRAI	US 1997-46346P	P	19970513		
AB	The invention relates to a method of decreasing body wt. in a patient. The method includes administering a therapeutically effective amt. of a type 5 selective somatostatin agonist to the patient.				
RE.CNT	65 THERE ARE 65 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT				

```
L2  ANSWER 2 OF 8  CAPLUS  COPYRIGHT 2002 ACS
AN  1998:764303  CAPLUS
DN  130:10642
TI  Method and compositions for treating hyperlipidemia and other
    conditions using a somatostatin type-5
    receptor agonist
IN  Cawthorne, Michael Anthony; Liu, Yong-Ling; Sennitt, Matthew V.
PA  Societe De Conseils De Recherches Et D'Applications Scientifiques S.A.
    (S.C., Fr.
SO  PCT Int. Appl., 31 pp.
    CODEN: PIXXD2
DT  Patent
LA  English
FAN.CNT 1
```

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9851330	A1	19981119	WO 1998-EP2998	19980513
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,				

UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,  
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,  
CM, GA, GN, ML, MR, NE, SN, TD, TG

AU 9880197 A1 19981208 AU 1998-80197 19980513  
EP 981364 A1 20000301 EP 1998-928307 19980513

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, FI

PRAI US 1997-855311 19970513  
WO 1998-EP2998 19980513

AB The present invention relates to a method of treating  
**hyperlipidemia** and to reducing triacylglycerols, glycerol and  
cholesterol in a patient. The method includes the step of administering a  
therapeutically effective amt. of a type-5 selective somatostatin agonist  
to said patient. A pharmaceutical compn. comprises said agonist and such  
product is used in the prepn. of the compn. for use in treating  
**hyperlipidemia** or reducing triacylglycerols, glycerol and  
cholesterol in a patient's body.

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 3 OF 8 USPATFULL

AN 2002:78717 USPATFULL

TI METHOD OF TREATING INSULIN INSENSITIVITY AND SYNDROME X

IN CAWTHORNE, MICHAEL ANTHONY, HORSHAM, UNITED KINGDOM

LIU, YONG-LING, BUCKINGHAM, UNITED KINGDOM

SENNITT, MATTHEW V., CHIPSTEAD, UNITED KINGDOM

PI US 2002042374 A1 20020411

AI US 1998-76948 A1 19980513 (9)

PRAI US 1997-46373P 19970513 (60)

DT Utility

FS APPLICATION

LREP JOHN D CONWAY, BIOMEASURE INC, 27 MAPLE STREET, MILFORD, MA, 017573650

CLMN Number of Claims: 30

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1115

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a method of treating insulin resistance  
or syndrome X in a patient. The method includes the step of  
administering a therapeutically effective amount of a somatostatin or a  
somatostatin agonist to said patient.

L2 ANSWER 4 OF 8 USPATFULL

AN 1999:166969 USPATFULL

TI Method of treating **hyperlipidemia**

IN Cawthorne, Michael Anthony, Horsham, United Kingdom

Liu, Yong-Ling, Buckingham, United Kingdom

Sennitt, Matthew V., Chipstead, United Kingdom

PA Biomeasure, Incorporated, Milford, MA, United States (U.S. corporation)

PI US 6004928 19991221

AI US 1998-78111 19980513 (9)

PRAI US 1997-46346P 19970513 (60)

DT Utility

FS Granted

EXNAM Primary Examiner: Russel, Jeffrey E.

LREP Conway, John D. Fish & Richardson

CLMN Number of Claims: 23

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 584

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a method of decreasing body weight in a  
patient. The method includes the step of administering a therapeutically  
effective amount of a type-5 selective somatostatin agonist to the

patient.

L2 ANSWER 5 OF 8 WPIDS (C) 2002 THOMSON DERWENT  
AN 2002-361791 [39] WPIDS  
DNC C2002-102310  
TI New imidazolyl derivatives, useful as selective agonists/antagonists of somatostatin receptors for treating acromegaly, restenosis, Crohn's disease and systemic sclerosis.  
DC B03  
IN BIGG, D; GALCERA, M; GORDON, T D; MOINET, C P; MORGAN, B A; POITOUT, L F; THURIEAU, C A  
PA (SCRC) SCRAS SOC CONSEILS RECH & APPL SCI  
CYC 94  
PI WO 2002010140 A2 20020207 (200239)\* EN 369p  
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZW  
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW  
AU 2001079098 A 20020213 (200239)  
ADT WO 2002010140 A2 WO 2001-US23959 20010731; AU 2001079098 A AU 2001-79098 20010731  
FDT AU 2001079098 A Based on WO 200210140  
PRAI US 2000-222584P 20000801  
AB WO 200210140 A UPAB: 20020621  
NOVELTY - Imidazolyl derivatives (I) or their racemic-diastereomeric-mixtures and optical isomers, salts, or prodrugs are new.  
DETAILED DESCRIPTION - Imidazolyl derivatives of formula (I) or their racemic-diastereomeric-mixtures and optical isomers, salts, or prodrugs are new.  
R1 = H, (CH2)mCO(CH2)mZ1, (CH2)mZ1, (CH2)mOZ1 or 0-6C-alkylC(O)NH(CH2)mZ1;  
Z1 = optionally substituted moiety selected from e.g. 1-12C alkyl, a group of formula e.g. (a), isoxazolyl or indolyl;  
R2 = H or 1-6C alkyl;  
R1+ R2 = taken together with the N atoms to which they are attached form a compound of formula (Ia)-(Ic)  
;  
R3 = (CH2)mE(CH2)mZ2;  
E = O, S, CO, CO2, NHC(O)O or a bond;  
Z2 = e.g. H, (1-12C)alkyl, or an optionally substituted moiety selected from e.g. phenyl;  
R4 = H or (CH2)mA1;  
A1 = C(=Y)-N(X1X2), C(=Y)X2, C(=NH)X2 or X2;  
Y = O or S;  
X1 = H, 1-12C alkyl, (CH2)mNH-1-6C alkyl or (CH2)m-N-di(1-6C) alkyl or (CH2)maryl;  
X2 = (CH2)mY1-X3 or optionally substituted (1-12C)alkyl;  
Y1 = O, S, NH, C=O, (2-12C)alkenyl having one or more double bonds, NHCO, CONH, NHCO2(CH2)m C triple bond C, SO2 or a bond;  
X3 = H, optionally substituted moiety selected from e.g. 1-12C alkyl, (CH2)mphenyl, or a group of formula e.g. (d):  
NX1X2 = optionally substituted moiety selected from thiazolyl or a group of formula e.g (m) or (p):  
;  
Y2 = CHX4, NX4, CX4X4, O or S;  
X4 = (CH2)mY3-X5;  
Y3 = C(O), CO2 or a bond;  
X5 = e.g. OH, 1-12C alkyl, or an optionally substituted moiety selected from e.g. aryl, CH(phenyl)2, or a group of formula (t):  
;  
R5 = (1-12C)alkyl, (0-6C)alkylCOOZ5, (0-6C)alkylC(O)NH(CH2)mZ3 or optionally substituted aryl;  
Z3 = e.g. amino, NHC(O)O(CH2)mphenyl, NHC(O)O(CH2)m-1-6C alkyl or an

optionally substituted moiety selected from e.g. imidazolyl;

R6 = H or 1-6C alkyl;

R7 = (1-12C)alkyl or (CH<sub>2</sub>)<sub>m</sub>Z<sub>4</sub>;

Z<sub>4</sub> = optionally substituted moiety selected from e.g. phenyl, or a group of formula e.g. (v):

;

Z<sub>5</sub> = H, 1-12C alkyl (CH<sub>2</sub>)<sub>m</sub>aryl;

where an optionally substituted moiety is optionally substituted by one or more e.g. Cl, (CH<sub>2</sub>)<sub>m</sub>phenyl-(X<sub>6</sub>)<sub>n</sub>, S-phenyl-(X<sub>6</sub>)<sub>n</sub>, S-(1-12C) alkyl, O(CH<sub>2</sub>)<sub>m</sub>phenyl-(X<sub>6</sub>)<sub>n</sub>, (CH<sub>2</sub>)<sub>m</sub>C(O)O-1-6C alkyl, (CH<sub>2</sub>)<sub>m</sub>C(O)-1-6C alkyl, O(CH<sub>2</sub>)<sub>m</sub>NH<sub>2</sub>, O(CH<sub>2</sub>)<sub>m</sub>NH-1-6C alkyl, O(CH<sub>2</sub>)<sub>m</sub>N-di-((1-6C)alkyl) or 0-12C alkyl-(X<sub>6</sub>)<sub>n</sub>;

X<sub>6</sub> = e.g. H, (CH<sub>2</sub>)<sub>m</sub>NH<sub>2</sub>, (CH<sub>2</sub>)<sub>m</sub>NH(1-6C)alkyl, (CH<sub>2</sub>)<sub>m</sub>NH(1-6C) alkyl, (CH<sub>2</sub>)<sub>m</sub>N-di-((1-6C)alkyl) or (CH<sub>2</sub>)<sub>m</sub>phenyl;

m = 0-6;

n = 1-5; and

with provisos.

The full definitions are given in the DEFINITIONS (Full Definitions) Field.

ACTIVITY - Osteopathic; vasotropic; antiinflammatory; cytostatic; antidiarrheic; dermatological; ophthalmological; immunomodulator; hypertensive; tranquilizer; antidiabetic; antilipemic; nephrotropic; antiulcer; immunosuppressive; antibacterial.

MECHANISM OF ACTION - Somatostatin receptor agonists; Somatostatin receptor antagonists (claimed).

An assay is described for assessing the affinity of compounds (I) for human somatostatin subtype receptors 1 to 5 (i.e. sst1, sst2, sst3, sst4 and sst5) by measuring the inhibition of (125)-Tyr11)SRIF-14 binding to CHO-K1 transfected cells, but no results are given.

USE - For treating acromegaly, restenosis, Crohn's disease, systemic sclerosis, external and internal pancreatic pseudocysts and ascites, VIPoma, nesidoblastosis, hyperinsulinism, gastrinoma, Zollinger-Ellison Syndrome, diarrhea, AIDS related diarrhea, chemotherapy related diarrhea, scleroderma, Irritable Bowel Syndrome, pancreatitis, small bowel obstruction, gastroesophageal reflux, duodenogastric reflux, Cushing's Syndrome, gonadotropinoma, hyperparathyroidism, Graves' Disease, diabetic neuropathy, Paget's disease, polycystic ovary disease, cancer, cancer cachexia, hypotension, postprandial hypotension, panic attacks, GH secreting adenomas or TSH secreting adenomas. For treating diabetes mellitus, hyperlipidemia, insulin insensitivity, Syndrome X, angiopathy, proliferative retinopathy, dawn phenomenon, nephropathy, peptic ulcers, enterocutaneous and pancreaticocutaneous fistula, Dumping syndrome, watery diarrhea syndrome, acute or chronic pancreatitis, gastrointestinal hormone secreting tumors, angiogenesis, inflammatory disorders, chronic allograft rejection, angioplasty, graft vessel bleeding or gastrointestinal bleeding. For inhibiting the proliferation of Helicobacter pylori.

ADVANTAGE - (I) are non-peptide, selective or potent somatostatin receptor ligands.

Dwg.0/0

L2 ANSWER 6 OF 8 WPIDS (C) 2002 THOMSON DERWENT

AN 2001-123000 [13] WPIDS

DNN N2001-090326 DNC C2001-035691

TI Peptide compounds are somatostatin agonists and useful for treating e.g. cancer, hypotension, restenosis, **hyperlipidemia**, scleroderma, psoriasis, pancreatitis, Crohn's disease, Grave's disease, acromegaly and panic attacks.

DC B04 S03

IN MORGAN, B A; SADAT-AALAE, D

PA (SCRC) SAS SOC CONSEILS RECH & APPL SCI; (SCRC) SCRAS SOC CONSEILS RECH & APPL SCI; (SCRC) SOC CONSEILS RECH & APPL SCI SAS

CYC 95

PI WO 2001000676 A1 20010104 (200113)\* EN 26p

RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ  
NL OA PT SD SE SL SZ TZ UG ZW

W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM  
DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC  
LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE  
SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AU 2000062000 A 20010131 (200124)

BR 2000011919 A 20020319 (200228)

EP 1189942 A1 20020327 (200229) EN

R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT  
RO SE SI

CZ 2001004534 A3 20020612 (200251)

ADT WO 2001000676 A1 WO 2000-US17401 20000623; AU 2000062000 A AU 2000-62000  
20000623; BR 2000011919 A BR 2000-11919 20000623, WO 2000-US17401  
20000623; EP 1189942 A1 EP 2000-948520 20000623, WO 2000-US17401 20000623;  
CZ 2001004534 A3 WO 2000-US17401 20000623, CZ 2001-4534 20000623

FDT AU 2000062000 A Based on WO 200100676; BR 2000011919 A Based on WO  
200100676; EP 1189942 A1 Based on WO 200100676; CZ 2001004534 A3 Based on  
WO 200100676

PRAI US 1999-141028P 19990625

AB WO 200100676 A UPAB: 20011129

NOVELTY - Peptide compounds (I) are new.

DETAILED DESCRIPTION - Peptide compounds of formula (I) and their  
salts are new.

X = H or a group of formula (i) or (ii);

A1, A3 = the D- or L-isomer of Phe, Tyr, Tyr(I), Trp, 3-Pal, 4-Pal,  
Cpa or Nal;

A4 = L-Trp, D-Trp, L- beta -methyl-Trp or D- beta -methyl-Trp;

A6 = NH-(CHR1)n-CO-;

n = 2-4;

A7 = L- or D-Cys;

A8 = D- or L-isomer of Phe, Tyr, Tyr(I), Trp, Nal, Cpa, Val, Leu,  
Ile, Ser or Thr;

Y = NR2R3;

R2, R3 = H or 1-5C alkyl;

R1 = H, 1-4C alkyl or CH2-aryl (optionally aryl substituted by  
phenyl, 1-naphthyl or 2-naphthyl (all optionally substituted by at least  
one 1-6C alkyl, 2-6C alkenyl, 2-6C alkynyl, aryl, aryl(1-6C alkyl), 1-6C  
alkoxy, -N(R4R5), COOH, CON(R4R5), halo, OH, CN or NO2); and

R4, R5 = H or 1-3C alkyl.

The Cys of A2 is bonded to the Cys of A7 by a disulfide bond formed  
from the thiol groups of each Cys.

An INDEPENDENT CLAIM is included for a method for eliciting a  
somatostatin agonist response in a human or other animal which comprises  
administration of a peptide of formula (I).

N.B. NaI is beta-(2-naphthyl)alanine, Cpa is p-chlorophenylalanine,  
3-Pal is beta-3-(pyridyl)alanine, 4-Pal is beta-4-pyridylalanine and Gaba  
is 4-aminobutyric acid

ACTIVITY - Osteopathic; cytostatic; antiinflammatory; hypertensive;  
dermatological; immunomodulator; vasotropic; antithyroid; antilipemic;  
gastrointestinal; anabolic; antidiarrheal; anti-AIDS; antisclerotic;  
antidiabetic; antiulcer; antihormonal; cardiant; circulatory active;  
antipsoriatic; tranquilizer.

MECHANISM OF ACTION - The peptides of formula (I) bind selectively to  
the **somatostatin subtype receptor 5** and are

**somatostatin** agonists and growth hormone secretion inhibitors.

Tests are described but no results are given.

USE - The peptides of formula (I) are useful for eliciting a  
somatostatin agonist response, for selectively binding a somatostatin  
subtype receptor type 5, for inhibiting the secretion of growth hormone,  
insulin, glucagon or pancreatic exocrine secretion and are useful for  
treating Cushing's syndrome, gonadotropinoma, hyperparathyroidism, Paget's  
disease, VIPoma, nesidioblastosis, hyperinsulinism, gastrinoma,  
Zollinger-Ellison syndrome, hypersecretory diarrhea related to AIDS and  
other conditions, irritable bowel syndrome, pancreatitis, Crohn's disease,  
systemic sclerosis, thyroid cancer, psoriasis, hypotension, panic attacks,  
scleroderma, small bowel obstruction, gastroesophageal reflux,

duodenogastric reflux, Grave's disease, polycystic ovary disease, upper gastrointestinal bleeding, pancreatic pseudocysts, pancreatic ascites, leukemia, meningioma, cancer, cachexia, acromegaly, restenosis, hepatoma, lung cancer, melanoma, inhibiting the accelerated growth of a solid tumor, decreasing body weight, treating insulin resistance, syndrome X, prolonging the survival of pancreatic cells, fibrosis, **hyperlipidemia**, hyperamylinemia, hyperprolactinemia and prolactinemia (claimed). (I) are also useful for imaging cells containing somatostatin receptors in vivo or in vitro provided that at least one of A1, A3 or A8 is Tyr(I) or a salt of Tyr(I) (claimed).  
Dwg.0/0

L2 ANSWER 7 OF 8 WPIDS (C) 2002 THOMSON DERWENT  
AN 2000-085796 [07] WPIDS  
DNC C2000-023951  
TI Method of treating **hyperlipidemia** using a **somatostatin** type-5 **receptor** agonist.  
DC B04  
IN CAWTHORNE, M A; LIU, Y; SENNITT, M V  
PA (BIOM-N) BIOMEASURE INC  
CYC 1  
PI US 6004928 A 19991221 (200007)\* 8p  
ADT US 6004928 A Provisional US 1997-46346P 19970513, US 1998-78111 19980513  
PRAI US 1997-46346P 19970513; US 1998-78111 19980513  
AB US 6004928 A UPAB: 20000209  
NOVELTY - Method of treating **hyperlipidemia** comprises administration of a **somatostatin** type-5 **receptor** agonist with a Ki of less than 2 nM.  
ACTIVITY - Antilipemic.  
11 male fatty Zucker rats weighing about 450 grams were randomly divided into 2 groups and their initial body weights recorded. The animals were housed in pairs in a normal 12 hour light/dark cycle at 20 plus or minus 2 deg. C and fed a standard laboratory diet overnight. In the treatment groups, rats received H-Cys-Phe-Phe-D-Trp-Lys-Thr-Phe-Cys-NH2 (BIM-23268) at 3 mg/kg by subcutaneous injection twice a day. The control group was treated with a subcutaneous injection of 0.1 l/100 g of saline twice a day. Both groups of animals were treated for 6 days.  
On the last day of treatment, food was removed at the second injection and the rats fasted overnight. The next day, the rats were subjected to a glucose challenge, given as 0.8 g/kg of glucose orally. Periodic 400 micro l of blood samples were taken from the tail vein at 60 and 30 minutes before, and at 30, 60, 90, 120 minutes after administration of the glucose challenge. Aprotinin and heparin were added to the blood samples to a final concentration of 400 KIU/ml and 100 units/ml, respectively. Plasma fractions were prepared and glycerol and triglycerides were determined using the Sigma Enzymatic (Tinder) calorimetric assay kit and measuring absorbance at 540 nm in a spectrophotometer.  
After 6 days of treatment with BIM-23268 at 3 mg/kg, twice a day by subcutaneous injection, both plasma glycerol and triglycerides were significantly lowered before the oral glucose challenge. The administration of the oral glucose challenge had no significant effect on plasma lipids. The BIM-23268 treated group showed significantly lower plasma glycerol and triglycerides through the 2 hour test period. The results suggested that BIM-23268, following a 6 day treatment period at the prescribed dose was effective in reducing hypertriglyceridemia.  
MECHANISM OF ACTION - Somatostatin receptor agonist.  
USE - The method is used to treat **hyperlipidemia** and to lower the amount of triacylglycerols, cholesterol (total cholesterol or low density lipoprotein cholesterol) or glycerol in the blood of a patient (all claimed).  
Dwg.0/0

L2 ANSWER 8 OF 8 WPIDS (C) 2002 THOMSON DERWENT  
AN 1999-059684 [05] WPIDS

DNC C1999-017521  
 TI Treating **hyperlipidaemia** with **somatostatin** type  
 5 **receptor** agonist - used to reduce blood levels of tri  
 acyl glycerol, glycerol and cholesterol, e.g. in diabetic patients.  
 DC B04  
 IN CAWTHORNE, M A; LIU, Y; SENNITT, M V  
 PA (SCRC) SCRAS SOC CONSEILS RECH & APPL SCI  
 CYC 83  
 PI WO 9851330 A1 19981119 (199905)\* EN 30p  
 RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL  
 OA PT SD SE SZ UG ZW  
 W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE  
 GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG  
 MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG  
 US UZ VN YU ZW  
 AU 9880197 A 19981208 (199916)  
 EP 981364 A1 20000301 (200016) EN  
 R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE  
 ADT WO 9851330 A1 WO 1998-EP2998 19980513; AU 9880197 A AU 1998-80197  
 19980513; EP 981364 A1 EP 1998-928307 19980513, WO 1998-EP2998 19980513  
 FDT AU 9880197 A Based on WO 9851330; EP 981364 A1 Based on WO 9851330  
 PRAI US 1997-855311 19970513  
 AB WO 9851330 A UPAB: 19990203  
 Treatment of **hyperlipidaemia** comprises administering a  
**somatostatin** type 5 **receptor** agonist (I). Also  
 new is lowering blood levels of triacylglycerols, glycerol and cholesterol  
 (total or as low-density lipoprotein) by administration of (I).  
 USE - The method is used to treat hyperlipaemic and/or diabetic  
 patients (human or animal) to reduce the risk of atherosclerosis and  
 ischaemic or coronary heart disease.  
 Dwg.0/0

=> dup rem l3  
 PROCESSING COMPLETED FOR L3  
 L7 12 DUP REM L3 (3 DUPLICATES REMOVED)

=> d l7 1-12 bib ab

L7 ANSWER 1 OF 12 USPATFULL  
 AN 2002:199078 USPATFULL  
 TI Modulating the activity of hormones or their receptors - peptides,  
 antibodies, vaccines and uses thereof  
 IN Kingston, David J., Glen Waverley, AUSTRALIA  
 Gerraty, Norman L., Mount Eliza, AUSTRALIA  
 Westbrook, Simon L., Balwyn, AUSTRALIA  
 PI US 2002107187 A1 20020808  
 AI US 2001-758128 A1 20010112 (9)  
 RLI Division of Ser. No. US 1999-194218, filed on 5 Feb 1999, ABANDONED A  
 371 of International Ser. No. WO 1997-AU312, filed on 22 May 1997,  
 UNKNOWN  
 PRAI AU 1996-9990 19960522  
 DT Utility  
 FS APPLICATION  
 LREP Stephen A. Bent, FOLEY & LARDNER, Washington Harbour, 3000 K Street,  
 N.W., Suite 500, Washington, DC, 20007-5109  
 CLMN Number of Claims: 38  
 ECL Exemplary Claim: 1  
 DRWN 19 Drawing Page(s)  
 LN.CNT 2312  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB This invention relates to immunogenic, non-naturally occurring peptides  
 and immunologically reactive molecules thereto which modulate the  
 activity of hormones or the receptors therefor. Methods of modulating  
 hormonal activity in an animal and compositions therefor are also

contemplated.

L7 ANSWER 2 OF 12 USPATFULL  
AN 2002:78717 USPATFULL  
TI METHOD OF TREATING INSULIN INSENSITIVITY AND SYNDROME X  
IN CAWTHORNE, MICHAEL ANTHONY, HORSHAM, UNITED KINGDOM  
LIU, YONG-LING, BUCKINGHAM, UNITED KINGDOM  
SENNITT, MATTHEW V., CHIPSTEAD, UNITED KINGDOM  
PI US 2002042374 A1 20020411  
AI US 1998-76948 A1 19980513 (9)  
PRAI US 1997-46373P 19970513 (60)  
DT Utility  
FS APPLICATION  
LREP JOHN D CONWAY, BIOMEASURE INC, 27 MAPLE STREET, MILFORD, MA, 017573650  
CLMN Number of Claims: 30  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 1115  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB The present invention relates to a method of treating insulin resistance or syndrome X in a patient. The method includes the step of administering a therapeutically effective amount of a somatostatin or a somatostatin agonist to said patient.

L7 ANSWER 3 OF 12 USPATFULL  
AN 2002:109060 USPATFULL  
TI Somatostatin agonists  
IN Zhou, Changyou, Plainsboro, NJ, United States  
Pasternak, Alexander, Princeton, NJ, United States  
Morriello, Gregori, Belleville, NJ, United States  
Guo, Liangqin, Edison, NJ, United States  
Pan, Yanping, Gaithersburg, MD, United States  
Yang, Lihu, Edison, NJ, United States  
Patchett, Arthur, Westfield, NJ, United States  
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)  
PI US 6387932 B1 20020514  
AI US 2000-595142 20000616 (9)  
PRAI US 1999-141096P 19990625 (60)  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Kifle, Bruck  
LREP McGinnis, James L., Rose, David L.  
CLMN Number of Claims: 12  
ECL Exemplary Claim: 1  
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)  
LN.CNT 1445  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB This invention relates to non-peptide somatostatin agonist compounds which are potent with high selectivity toward the receptor subtype 2. The compounds provide an improved therapeutic index in the treatment of diabetes, cancer, acromegaly and retinosis. Many of the compounds are orally active.

L7 ANSWER 4 OF 12 USPATFULL  
AN 2001:59682 USPATFULL  
TI DNA encoding SNORF25 receptor  
IN Bonini, James A., Oakland, NJ, United States  
Borowsky, Beth E., Montclair, NJ, United States  
Adham, Nika, Ridgewood, NJ, United States  
Boyle, Noel, Cliffside Park, NJ, United States  
Thompson, Thelma O., Passaic Park, NJ, United States  
PA Synaptic Pharmaceutical Corporation, Paramus, NJ, United States (U.S. corporation)  
PI US 6221660 B1 20010424  
AI US 1999-387699 19990813 (9)

RLI Continuation-in-part of Ser. No. US 1999-255376, filed on 22 Feb 1999  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Spector, Lorraine; Assistant Examiner: O'Hara, Eileen B.  
LREP White, John P. Cooper & Dunham LLP  
CLMN Number of Claims: 21  
ECL Exemplary Claim: 1  
DRWN 16 Drawing Figure(s); 14 Drawing Page(s)  
LN.CNT 2877

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides isolated nucleic acids encoding mammalian SNORF25 receptors, purified mammalian SNORF25 receptors, vectors comprising nucleic acid encoding mammalian SNORF25 receptors, cells comprising such vectors, antibodies directed to mammalian SNORF25 receptors, nucleic acid probes useful for detecting nucleic acid encoding mammalian SNORF25 receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding mammalian SNORF25 receptors, transgenic, nonhuman animals which express DNA encoding normal or mutant mammalian SNORF25 receptors, methods of isolating mammalian SNORF25 receptors, methods of treating an abnormality that is linked to the activity of the mammalian SNORF25 receptors, as well as methods of determining binding of compounds to mammalian SNORF25 receptors, methods of identifying agonists and antagonists of SNORF25 receptors, and agonists and antagonists so identified.

L7 ANSWER 5 OF 12 USPATFULL

AN 2000:121523 USPATFULL

TI Somatostatin agonists

IN Guo, Liangquin, Edison, NJ, United States  
Mosley, Ralph T., Roselle, NJ, United States  
Pasternak, Alexander, Princeton, NJ, United States  
Patchett, Arthur A., Westfield, NJ, United States  
Yang, Lihu, Edison, NJ, United States

PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

PI US 6117880 20000912

AI US 1998-181590 19981028 (9)

DT Utility

FS Granted

EXNAM Primary Examiner: Chang, Ceila

LREP McGinnis, James L., Rose, David L.

CLMN Number of Claims: 14

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1815

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to somatostatin agonist compounds which are potent with high selectivity toward the receptor subtype 2. The compounds provide an improved therapeutic index in the treatment of diabetes, cancer, acromegaly and retinosis. Many of the compounds are also orally active. Thus, it is an object of this invention to describe such compounds. It is a further object to describe the specific preferred stereoisomers of the somatostatin agonists. A still further object is to describe processes for the preparation of such compounds. Another object is to describe methods and compositions which use the compounds as the active ingredient thereof. Further objects will become apparent from reading the following description.

L7 ANSWER 6 OF 12 USPATFULL

AN 2000:61612 USPATFULL

TI Somatostatin agonists

IN Yang, Lihu, Edison, NJ, United States  
Pachett, Arthur A., Westfield, NJ, United States  
Pasternak, Alexander, Princeton, NJ, United States

Berk, Scott, Maplewood, NJ, United States  
Chen, Meng Hsin, Westfield, NJ, United States  
Johnston, David, Warren, NJ, United States  
Chapman, Kevin, Scotch Plains, NJ, United States  
Nargund, Ravi, East Brunswick, NJ, United States  
Tata, James R., Westfield, NJ, United States  
Guo, Liangqin, Edison, NJ, United States

PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

PI US 6063796 20000516

AI US 1998-53299 19980401 (9)

PRAI US 1997-42637P 19970404 (60)

US 1997-64378P 19971106 (60)

DT Utility

FS Granted

EXNAM Primary Examiner: Chang, Ceila

LREP McGinnis, James L., Rose, David L.

CLMN Number of Claims: 13

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 2678

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to somatostatin agonist compounds which are potent with high selectivity toward the receptor subtype 2. Compounds of the formula: ##STR1## including pharmaceutically acceptable salts and hydrates thereof are disclosed. These compounds are useful in the treatment of diabetes, cancer, acromegaly, restenosis, depression, irritable bowel syndrome, pain and diabetic retinopathy. Many of the compounds are also orally active.

L7 ANSWER 7 OF 12 USPATFULL

AN 2000:54121 USPATFULL

TI Somatostatin agonists

IN Yang, Lihu, Edison, NJ, United States

Patchett, Arthur A., Westfield, NJ, United States

Pasternak, Alexander, Princeton, NJ, United States

Berk, Scott, Maplewood, NJ, United States

PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

PI US 6057338 20000502

AI US 1998-53244 19980401 (9)

PRAI US 1997-42633P 19970404 (60)

US 1997-64381P 19971106 (60)

DT Utility

FS Granted

EXNAM Primary Examiner: Chang, Ceila

LREP McGinnis, James L., Rose, David L.

CLMN Number of Claims: 23

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 2520

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to somatostatin agonist compounds which are potent with high selectivity toward the receptor subtype 2. Compounds of the formula: ##STR1## including pharmaceutically acceptable salts and hydrates thereof are disclosed. These compounds are useful in the treatment of diabetes, cancer, acromegaly, restenosis, depression, irritable bowel syndrome, pain and diabetic retinopathy. Many of the compounds are also orally active.

L7 ANSWER 8 OF 12 USPATFULL

AN 2000:18457 USPATFULL

TI Somatostatin agonists

IN Yang, Lihu, Edison, NJ, United States

Patchett, Arthur A., Westfield, NJ, United States

Pasternak, Alexander, Princeton, NJ, United States

Chapman, Kevin, Scotch Plains, NJ, United States

Tata, James R., Westfield, NJ, United States  
Guo, Liangqin, Edison, NJ, United States  
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)  
PI US 6025372 20000215  
AI US 1998-53373 19980401 (9)  
PRAI US 1997-42920P 19970414 (60)  
US 1997-64380P 19971106 (60)

DT Utility

FS Granted

EXNAM Primary Examiner: Chang, Ceila

LREP McGinnis, James L., Rose, David L., Billups, Richard C.

CLMN Number of Claims: 19

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 2508

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Somatostatin agonist compounds of formula I are disclosed: ##STR1## including pharmaceutically acceptable salts and hydrates thereof These compounds are useful in the treatment of diabetes, cancer, acromegaly, restenosis, depression, irritable bowel syndrome and pain. The compounds are potent with high selectivity toward the receptor subtype 2.

Pharmaceutical compositions and methods of treatment are also included.

L7 ANSWER 9 OF 12 USPATFULL

AN 2000:12620 USPATFULL

TI Polynucleotides encoding HFGAN72X receptor

IN Bergsma, Derk J., Berwyn, PA, United States

Ellis, Catherine Elizabeth, Glassboro, NJ, United States

PA SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)

PI US 6020157 20000201

AI US 1997-846704 19970430 (8)

DT Utility

FS Granted

EXNAM Primary Examiner: Teng, Sally P.

LREP Hecht, Elizabeth J., Han, William T., King, William T.

CLMN Number of Claims: 11

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1380

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB HFGAN72X polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing HFGAN72X polypeptides and polynucleotides in the design of protocols for the treatment of infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; anorexia; bulimia; asthma; Parkinson's disease; acute heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; ulcers; asthma; allergies; benign prostatic hypertrophy; and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles de la Tourette's syndrome, among others and diagnostic assays for such conditions.

L7 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 1

AN 1999:808645 CAPLUS

DN 132:44983

TI Method using a type 5 selective somatostatin agonist for treating hyperlipidemia

IN Cawthorne, Michael Anthony; Liu, Yong-Ling; Sennitt, Matthew V.

PA Biomeasure, Incorporated, USA

SO U.S., 8 pp.

CODEN: USXXAM

DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
--	------------	------	------	-----------------	------

PI	US 6004928	A	19991221	US 1998-78111	19980513
PRAI	US 1997-46346P	P	19970513		

AB The invention relates to a method of decreasing body wt. in a patient.  
The method includes administering a therapeutically effective amt. of a  
type 5 selective somatostatin agonist to the patient.

RE.CNT 65 THERE ARE 65 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 11 OF 12 USPATFULL

AN 1999:92531 USPATFULL

TI Polynucleotides encoding HFGAN72Y receptor

IN Bergsma, Derk J., Berwyn, PA, United States

Ellis, Catherine Elizabeth, Glassboro, NJ, United States

PA Smithkline Beecham Corporation, Philadelphia, PA, United States (U.S.  
corporation)

PI US 5935814 19990810

AI US 1997-846705 19970430 (8)

DT Utility

FS Granted

EXNAM Primary Examiner: Teng, Sally P.

LREP Hecht, Elizabeth J., Han, William T., King, William T.

CLMN Number of Claims: 15

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1336

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB HFGAN72Y polypeptides and polynucleotides and methods for producing such  
polypeptides by recombinant techniques are disclosed. Also disclosed are  
methods for utilizing HFGAN72Y polypeptides and polynucleotides in the  
design of protocols for the treatment of infections such as bacterial,  
fungal, protozoan and viral infections, particularly infections caused  
by HIV-1 or HIV-2; pain; cancers; anorexia; bulimia; asthma; Parkinson's  
disease; acute heart failure; hypotension; hypertension; urinary  
retention; osteoporosis; angina pectoris; myocardial infarction; ulcers;  
asthma; allergies; benign prostatic hypertrophy; and psychotic and  
neurological disorders, including anxiety, schizophrenia, manic  
depression, delirium, dementia, severe mental retardation and  
dyskinesias, such as Huntington's disease or Gilles de la Tourette's  
syndrome, among others and diagnostic assays for such conditions.

L7 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 2

AN 1998:764303 CAPLUS

DN 130:10642

TI Method and compositions for treating hyperlipidemia and other conditions  
using a **somatostatin** type-5 **receptor** agonist

IN Cawthorne, Michael Anthony; Liu, Yong-Ling; Sennitt, Matthew V.

PA Societe De Conseils De Recherches Et D'Applications Scientifiques S.A.  
(S.C., Fr.

SO PCT Int. Appl., 31 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
--	------------	------	------	-----------------	------

PI	WO 9851330	A1	19981119	WO 1998-EP2998	19980513
----	------------	----	----------	----------------	----------

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,  
DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG,  
KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX,  
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,

UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,  
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,  
CM, GA, GN, ML, MR, NE, SN, TD, TG

AU 9880197 A1 19981208 AU 1998-80197 19980513

EP 981364 A1 20000301 EP 1998-928307 19980513

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, FI

PRAI US 1997-855311 19970513

WO 1998-EP2998 19980513

AB The present invention relates to a method of treating hyperlipidemia and to reducing triacylglycerols, **glycerol** and cholesterol in a patient. The method includes the step of administering a therapeutically effective amt. of a type-5 selective somatostatin agonist to said patient. A pharmaceutical compn. comprises said agonist and such product is used in the prepn. of the compn. for use in treating hyperlipidemia or reducing triacylglycerols, **glycerol** and cholesterol in a patient's body.

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 18:36:44 ON 08 SEP 2002)

FILE 'MEDLINE, CAPLUS, BIOSIS, BIOTECHDS, EMBASE, USPATFULL, WPIDS'  
ENTERED AT 18:37:04 ON 08 SEP 2002

L1 579 S (SOMATOSTATIN (2A) 5 (2A) RECEPTOR# OR SSTR(W)5)  
L2 8 S L1 AND (HYPERLIPID? OR LIPIDEM?)  
L3 15 S L1 AND (TRIACYGLYCEROL OR GLYCEROL OR CHOLESTROL)  
L4 6 S L2 AND L3  
L5 15 S L3 AND (TREAT? OR LOWER?)  
L6 6 S L2 AND L5  
L7 12 DUP REM L3 (3 DUPLICATES REMOVED)

=> d l6 1-6 bib ab

L6 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2002 ACS

AN 1999:808645 CAPLUS

DN 132:44983

TI Method using a type 5 selective somatostatin agonist for **treating hyperlipidemia**

IN Cawthorne, Michael Anthony; Liu, Yong-Ling; Sennitt, Matthew V.

PA Biomeasure, Incorporated, USA

SO U.S., 8 pp.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

PI US 6004928	A	19991221	US 1998-78111	19980513
---------------	---	----------	---------------	----------

PRAI US 1997-46346P	P	19970513		
---------------------	---	----------	--	--

AB The invention relates to a method of decreasing body wt. in a patient. The method includes administering a therapeutically effective amt. of a type 5 selective somatostatin agonist to the patient.

RE.CNT 65 THERE ARE 65 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2002 ACS

AN 1998:764303 CAPLUS

DN 130:10642

TI Method and compositions for **treating hyperlipidemia** and other conditions using a **somatostatin type-5 receptor** agonist

IN Cawthorne, Michael Anthony; Liu, Yong-Ling; Sennitt, Matthew V.  
PA Societe De Conseils De Recherches Et D'Applications Scientifiques S.A.  
(S.C., Fr.  
SO PCT Int. Appl., 31 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9851330	A1	19981119	WO 1998-EP2998	19980513
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	AU 9880197	A1	19981208	AU 1998-80197	19980513
	EP 981364	A1	20000301	EP 1998-928307	19980513
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			

PRAI US 1997-855311 19970513  
WO 1998-EP2998 19980513

AB The present invention relates to a method of **treating hyperlipidemia** and to reducing triacylglycerols, **glycerol** and cholesterol in a patient. The method includes the step of administering a therapeutically effective amt. of a type-5 selective somatostatin agonist to said patient. A pharmaceutical compn. comprises said agonist and such product is used in the prepn. of the compn. for use in **treating hyperlipidemia** or reducing triacylglycerols, **glycerol** and cholesterol in a patient's body.

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 6 USPATFULL

AN 2002:78717 USPATFULL

TI METHOD OF **TREATING** INSULIN INSENSITIVITY AND SYNDROME X

IN CAWTHORNE, MICHAEL ANTHONY, HORSHAM, UNITED KINGDOM

LIU, YONG-LING, BUCKINGHAM, UNITED KINGDOM

SENNITT, MATTHEW V., CHIPSTEAD, UNITED KINGDOM

PI US 2002042374 A1 20020411

AI US 1998-76948 A1 19980513 (9)

PRAI US 1997-46373P 19970513 (60)

DT Utility

FS APPLICATION

LREP JOHN D CONWAY, BIOMEASURE INC, 27 MAPLE STREET, MILFORD, MA, 017573650

CLMN Number of Claims: 30

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1115

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a method of **treating** insulin resistance or syndrome X in a patient. The method includes the step of administering a therapeutically effective amount of a somatostatin or a somatostatin agonist to said patient.

L6 ANSWER 4 OF 6 USPATFULL

AN 1999:166969 USPATFULL

TI Method of **treating hyperlipidemia**

IN Cawthorne, Michael Anthony, Horsham, United Kingdom

Liu, Yong-Ling, Buckingham, United Kingdom

Sennitt, Matthew V., Chipstead, United Kingdom

PA Biomeasure, Incorporated, Milford, MA, United States (U.S. corporation)

PI US 6004928 19991221  
AI US 1998-78111 19980513 (9)  
PRAI US 1997-46346P 19970513 (60)  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Russel, Jeffrey E.  
LREP Conway, John D. Fish & Richardson  
CLMN Number of Claims: 23  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 584

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a method of decreasing body weight in a patient. The method includes the step of administering a therapeutically effective amount of a type-5 selective somatostatin agonist to the patient.

L6 ANSWER 5 OF 6 WPIDS (C) 2002 THOMSON DERWENT

AN 2000-085796 [07] WPIDS

DNC C2000-023951

TI Method of **treating hyperlipidemia** using a **somatostatin type-5 receptor** agonist.

DC B04

IN CAWTHORNE, M A; LIU, Y; SENNITT, M V

PA (BIOM-N) BIOMEASURE INC

CYC 1

PI US 6004928 A 19991221 (200007)\* 8p

ADT US 6004928 A Provisional US 1997-46346P 19970513, US 1998-78111 19980513

PRAI US 1997-46346P 19970513; US 1998-78111 19980513

AB US 6004928 A UPAB: 20000209

NOVELTY - Method of **treating hyperlipidemia** comprises administration of a **somatostatin type-5 receptor** agonist with a  $K_i$  of less than 2 nM.

ACTIVITY - Antilipemic.

11 male fatty Zucker rats weighing about 450 grams were randomly divided into 2 groups and their initial body weights recorded. The animals were housed in pairs in a normal 12 hour light/dark cycle at 20 plus or minus 2 deg. C and fed a standard laboratory diet overnight. In the **treatment** groups, rats received H-Cys-Phe-Phe-D-Trp-Lys-Thr-Phe-Cys-NH<sub>2</sub> (BIM-23268) at 3 mg/kg by subcutaneous injection twice a day. The control group was **treated** with a subcutaneous injection of 0.1 l/100 g of saline twice a day. Both groups of animals were **treated** for 6 days.

On the last day of **treatment**, food was removed at the second injection and the rats fasted overnight. The next day, the rats were subjected to a glucose challenge, given as 0.8 g/kg of glucose orally. Periodic 400 micro l of blood samples were taken from the tail vein at 60 and 30 minutes before, and at 30, 60, 90, 120 minutes after administration of the glucose challenge. Aprotinin and heparin were added to the blood samples to a final concentration of 400 KIU/ml and 100 units/ml, respectively. Plasma fractions were prepared and **glycerol** and triglycerides were determined using the Sigma Enzymatic (Tinder) calorimetric assay kit and measuring absorbance at 540 nm in a spectrophotometer.

After 6 days of **treatment** with BIM-23268 at 3 mg/kg, twice a day by subcutaneous injection, both plasma **glycerol** and triglycerides were significantly **lowered** before the oral glucose challenge. The administration of the oral glucose challenge had no significant effect on plasma lipids. The BIM-23268 **treated** group showed significantly **lower** plasma **glycerol** and triglycerides through the 2 hour test period. The results suggested that BIM-23268, following a 6 day **treatment** period at the prescribed dose was effective in reducing hypertriglyceridemia.

MECHANISM OF ACTION - Somatostatin receptor agonist.

USE - The method is used to **treat hyperlipidemia**

and to **lower** the amount of triacylglycerols, cholesterol (total cholesterol or low density lipoprotein cholesterol) or **glycerol** in the blood of a patient (all claimed).  
Dwg.0/0

L6 ANSWER 6 OF 6 WPIDS (C) 2002 THOMSON DERWENT

AN 1999-059684 [05] WPIDS

DNC C1999-017521

TI **Treating hyperlipidaemia with somatostatin**  
type 5 receptor agonist - used to reduce blood levels  
of tri acyl **glycerol**, **glycerol** and cholesterol, e.g.  
in diabetic patients.

DC B04

IN CAWTHORNE, M A; LIU, Y; SENNITT, M V

PA (SCRC) SCRAS SOC CONSEILS RECH & APPL SCI

CYC 83

PI WO 9851330 A1 19981119 (199905)\* EN 30p

RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL  
OA PT SD SE SZ UG ZW

W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE  
GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG  
MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG  
US UZ VN YU ZW

AU 9880197 A 19981208 (199916)

EP 981364 A1 20000301 (200016) EN

R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

ADT WO 9851330 A1 WO 1998-EP2998 19980513; AU 9880197 A AU 1998-80197  
19980513; EP 981364 A1 EP 1998-928307 19980513, WO 1998-EP2998 19980513

FDT AU 9880197 A Based on WO 9851330; EP 981364 A1 Based on WO 9851330

PRAI US 1997-855311 19970513

AB WO 9851330 A UPAB: 19990203

**Treatment of hyperlipidaemia** comprises administering a  
**somatostatin** type 5 receptor agonist (I). Also  
new is **lowering** blood levels of triacylglycerols,  
**glycerol** and cholesterol (total or as low-density lipoprotein) by  
administration of (I).

USE - The method is used to **treat** hyperlipaemic and/or  
diabetic patients (human or animal) to reduce the risk of atherosclerosis  
and ischaemic or coronary heart disease.

Dwg.0/0

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

STN INTERNATIONAL LOGOFF AT 18:55:01 ON 08 SEP 2002